News | November 03, 2021
Venus Remedies H1 net profit rises 315%
Venus Remedies has reported consolidated financial results for the period ended September 30, 2021
Venus Remedies has reported consolidated financial results for the period ended September 30, 2021
Following the review of around 20 candidate vaccines by the external advisory group, MVC's vaccine was selected as one of two to be included in the global trial
It answers the most basic questions from a patient’s perspective
A total of 12 generic medicines have been included in the list
Expands wound care portfolio and aims to drive greater market penetration and availability in the wound dressing category
A total of Rs 17,691.08 cr. invested in 157 new approved medical colleges since 2014
This strategic collaboration will enable continued innovation in cancer care
The platform has seen an overall growth of 84% in the number of people seeking consultations for skin-related issues
The company proposes to invest up to US $ 50 million, over a period of five years, starting from FY22, to support capability development of talent and technology
The interim analysis showed that the MVC-COV1901 vaccine has a good safety profile and elicits promising neutralising antibody titres
Subscribe To Our Newsletter & Stay Updated
